Samuele Renzi1,2, Karin Petra Sabine Langenberg-Ververgaert3, Nicolas Waespe4,5,6, Salah Ali4,7, Jack Bartram4,8, Orli Michaeli4,7, Julia Upton7,9, Michaela Cada4,7. 1. Division of Haematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G1X8, Canada. samuele.renzi@sickkids.ca. 2. University of Toronto, Toronto, Ontario, Canada. samuele.renzi@sickkids.ca. 3. Department of Translational Research, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. 4. Division of Haematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G1X8, Canada. 5. Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 6. CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland. 7. University of Toronto, Toronto, Ontario, Canada. 8. Department of Haematology, Great Ormond Street Hospital for Children, London, UK. 9. Division of Immunology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Abstract
Primary immunodeficiency disorders represent a heterogeneous spectrum of diseases, predisposing to recurrent infections, allergy, and autoimmunity. While an association between primary immunodeficiency disorders and increased risk of cancer has been suggested since the 1970s, renewed attention has been given to this topic in the last decade, largely in light of the availability of large registries as well as advances in next generation sequencing. In this narrative review, we will give an insight of the primary immunodeficiencies that are commonly responsible for the greater number of cancers in the primary immunodeficiency disorders population. We will describe clinical presentations, underlying genetic lesions (if known), molecular mechanisms for carcinogenesis, as well as some management considerations. We will also comment on the future directions and challenges related to this topic. Conclusion: The awareness of the association between several primary immunodeficiencies and cancer is crucial to provide the best care for these patients.What is Known: • Patients with primary immunodeficiency have an increased risk of malignancy. The type of malignancy is highly dependent on the specific primary immunodeficiency disorder.What is New: • Survival in patients with primary immunodeficiency disorders has been improving, and conversely also their lifetime risk of malignancy. • International collaboration and multinational registries are needed to improve our knowledge and therapeutic strategies.
Primary immunodeficiency disorders represent a heterogeneous spectrum of diseases, predisposing to recurrent infections, allergy, and autoimmunity. While an association between primary immunodeficiency disorders and increased risk of cancer has been suggested since the 1970s, renewed attention has been given to this topic in the last decade, largely in light of the availability of large registries as well as advances in next generation sequencing. In this narrative review, we will give an insight of the primary immunodeficiencies that are commonly responsible for the greater number of cancers in the primary immunodeficiency disorders population. We will describe clinical presentations, underlying genetic lesions (if known), molecular mechanisms for carcinogenesis, as well as some management considerations. We will also comment on the future directions and challenges related to this topic. Conclusion: The awareness of the association between several primary immunodeficiencies and cancer is crucial to provide the best care for these patients.What is Known: • Patients with primary immunodeficiency have an increased risk of malignancy. The type of malignancy is highly dependent on the specific primary immunodeficiency disorder.What is New: • Survival in patients with primary immunodeficiency disorders has been improving, and conversely also their lifetime risk of malignancy. • International collaboration and multinational registries are needed to improve our knowledge and therapeutic strategies.
Authors: Markus G Seidel; Gerhard Kindle; Benjamin Gathmann; Isabella Quinti; Matthew Buckland; Joris van Montfrans; Raphael Scheible; Stephan Rusch; Lukas M Gasteiger; Bodo Grimbacher; Nizar Mahlaoui; Stephan Ehl Journal: J Allergy Clin Immunol Pract Date: 2019-02-15
Authors: Susan Price; Pamela A Shaw; Amy Seitz; Gyan Joshi; Joie Davis; Julie E Niemela; Katie Perkins; Ronald L Hornung; Les Folio; Philip S Rosenberg; Jennifer M Puck; Amy P Hsu; Bernice Lo; Stefania Pittaluga; Elaine S Jaffe; Thomas A Fleisher; V Koneti Rao; Michael J Lenardo Journal: Blood Date: 2014-01-07 Impact factor: 22.113
Authors: Benjamin Gathmann; Nizar Mahlaoui; Laurence Gérard; Eric Oksenhendler; Klaus Warnatz; Ilka Schulze; Gerhard Kindle; Taco W Kuijpers; Rachel T van Beem; David Guzman; Sarita Workman; Pere Soler-Palacín; Javier De Gracia; Torsten Witte; Reinhold E Schmidt; Jiri Litzman; Eva Hlavackova; Vojtech Thon; Michael Borte; Stephan Borte; Dinakantha Kumararatne; Conleth Feighery; Hilary Longhurst; Matthew Helbert; Anna Szaflarska; Anna Sediva; Bernd H Belohradsky; Alison Jones; Ulrich Baumann; Isabelle Meyts; Necil Kutukculer; Per Wågström; Nermeen Mouftah Galal; Joachim Roesler; Evangelia Farmaki; Natalia Zinovieva; Peter Ciznar; Efimia Papadopoulou-Alataki; Kirsten Bienemann; Sirje Velbri; Zoya Panahloo; Bodo Grimbacher Journal: J Allergy Clin Immunol Date: 2014-02-28 Impact factor: 10.793
Authors: Christopher C Porter; Todd E Druley; Ayelet Erez; Roland P Kuiper; Kenan Onel; Joshua D Schiffman; Kami Wolfe Schneider; Sarah R Scollon; Hamish S Scott; Louise C Strong; Michael F Walsh; Kim E Nichols Journal: Clin Cancer Res Date: 2017-06-01 Impact factor: 12.531
Authors: Krystyna H Chrzanowska; Hanna Gregorek; Bożenna Dembowska-Bagińska; Maria A Kalina; Martin Digweed Journal: Orphanet J Rare Dis Date: 2012-02-28 Impact factor: 4.123
Authors: Anne P J de Pagter; Robbert G M Bredius; Taco W Kuijpers; Jelco Tramper; Mirjam van der Burg; Joris van Montfrans; Gertjan J Driessen Journal: Eur J Pediatr Date: 2015-04-01 Impact factor: 3.183
Authors: Pavlina Kralickova; Tomas Milota; Jiri Litzman; Ivana Malkusova; Dalibor Jilek; Jitka Petanova; Jana Vydlakova; Alena Zimulova; Eva Fronkova; Michael Svaton; Veronika Kanderova; Marketa Bloomfield; Zuzana Parackova; Adam Klocperk; Jiri Haviger; Tomas Kalina; Anna Sediva Journal: Front Immunol Date: 2019-01-22 Impact factor: 7.561